

Supplementary Table 1. NCI-MATCH subprotocols with published results

#	Journal	Subprotocol	Title	Objective Response Rate (ORR)
1	Annals of Oncology	Q	Ado-trastuzumab emtansine (T-DM1) in patients with HER2 amplified tumors excluding breast and gastric/gastro-esophageal junction (GEJ) adenocarcinomas: Results from the NCI-MATCH Trial (EAY131) Subprotocol Q Jhaveri KL. <i>Ann Oncol.</i> 2019; 30:1821	5.6%
2	Journal of Clinical Oncology	Z1D	Nivolumab Is Effective in Mismatch Repair–Deficient Noncolorectal Cancers: Results From Arm Z1D—A Subprotocol of the NCI-MATCH (EAY131) Study Azad NS. <i>J Clin Oncol.</i> 2020; 38:214	36%
3	Clinical Cancer Research	R	Trametinib activity in patients with solid tumors and lymphomas harboring BRAF non-V600 mutations or fusions: Results from NCI-MATCH (EAY131) Johnson DB. <i>Clin Cancer Res.</i> 2020; 26:1812	3%
4	Journal of Clinical Oncology	W	Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W Chae YK. <i>J Clin Oncol.</i> 2020; 38:2407	8%
5	Journal of Clinical Oncology	H	Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H Salama AKS. <i>J Clin Oncol.</i> 2020; 38:3895	37.5%
6	JAMA Oncology	Y	Effect of Capivasertib in Patients with an AKT1 E17K-mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial Kalinsky KM. <i>JAMA Oncol.</i> 2021; 7:271	28.6%
7	Clinical Cancer Research	Z1A	Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase 2 NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors Cleary JM. <i>Clin Cancer Res.</i> 2021; 27:2996	2.1%
8	Journal of Clinical Oncology	I	Phase II Study of Taselisib in PIK3CA Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I Krop IE. <i>JCO Precis Oncol.</i> 2022;6:e2100424	0%
9	Journal of Clinical Oncology	Z1F	Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F Damodaran S. <i>J Clin Oncol.</i> 2022; 40:1552	16%
10	NPJ Precision Oncology	F, G	Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial Mansfield AS. <i>NPJ Precis Oncol.</i> 2022; 6:13	50%, 25%
11	Journal of Clinical Oncology	B	Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2–Activating Mutations: Results From the National Cancer Institute–Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-B Bedard PL. <i>JCO Precis Oncol.</i> 2022; 6:e2200165	2.7%